Malignant biphasic mesothelioma

Summary

Malignant biphasic mesothelioma (MONDO:0006109) is a disease and 2 clinical trials. Top therapeutic interventions include pembrolizumab. A subtype of malignant mesothelioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant biphasic mesothelioma
Mondo ID	MONDO:0006109
EFO	EFO:1000124
DOID	DOID:4486
NCIT	C4282
UMLS	C0334515
MedGen	137775
GARD	0024296
Is cancer (heuristic)	no

Also known as: biphasic mesothelioma · malignant biphasic mesothelioma · malignant biphasic mesothelioma, malignant · malignant mixed mesothelioma · mesothelioma, biphasic, malignant (morphologic abnormality) · mixed mesothelioma

Disease family

This is a subtype of malignant mesothelioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mesothelioma › malignant biphasic mesothelioma

Related subtypes (10): ovarian malignant mesothelioma, malignant pericardial mesothelioma, malignant pleural mesothelioma, malignant peritoneal mesothelioma, malignant epithelioid mesothelioma, sarcomatoid mesothelioma, localized pleural mesothelioma, diffused pleural mesothelioma, pleural mesothelioma in situ, mesothelioma of the tunica vaginalis

Subtypes (1): pleural biphasic mesothelioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02399371	PHASE2	COMPLETED	Pembrolizumab in Treating Patients With Malignant Mesothelioma
NCT03228537	PHASE1	ACTIVE_NOT_RECRUITING	Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMBROLIZUMAB	4	1